DOCSLIB.ORG

ECP) in the Treatment of Chronic Graft- Versus-Host Disease (GVHD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ECP) in the Treatment of Chronic Graft- Versus-Host Disease (GVHD Bone Marrow Transplantation, (1999) 23, 881–887 1999 Stockton Press All rights reserved 0268–3369/99 $12.00 http://www.stockton-press.co.uk/bmt Extracorporeal photopheresis (ECP) in the treatment of chronic graft- versus-host disease (GVHD) FJ Child1, R Ratnavel1, P Watkins1, D Samson2, J Apperley2, J Ball3, P Taylor3 and R Russell-Jones1 1Skin Tumour Unit, St John’s Institute of Dermatology, St Thomas’ Hospital, London; 2Department of Haematology, Hammersmith Hospital, London; and 3Department of Haematology, Rotherham District General Hospital, Rotherham, UK Summary: morbidity and mortality. Acute GVHD affects 40–50% of allogeneic stem cell transplant recipients and chronic The aim of our study was to assess the efficacy of extra- GVHD affects 30–50% of those surviving the acute phase corporeal photopheresis (ECP) in chronic graft-versus- of transplantation.1,2 host disease (GVHD). Eleven patients with chronic Prevention of GVHD is important because treatment of cutaneous GVHD were studied. Four had mucosal established disease is often unsatisfactory. Measures such involvement and five had pulmonary involvement. All as pre-transplant T cell depletion and immunosuppression had failed to improve on first- and second-line therapy. with methotrexate, cyclosporin A and prednisolone are Three patients received ECP alone; the remainder con- routinely undertaken. tinued to receive steroids and/or immunosuppressive Chronic GVHD may be limited to localised skin involve- therapy. Patients received ECP twice monthly for 4 ment and liver dysfunction, or the disease may be more months and then once monthly for 3 months. They were extensive with generalised skin involvement and additional evaluated by serial skin scores, mucosal and skin pho- organ involvement. Patients with limited disease may not tography, pulmonary function tests, biochemical and require any treatment; however, those with extensive dis- haematological parameters. Nine patients showed objec- ease require treatment to decrease the chance of progression tive evidence of cutaneous improvement with a mean to end stage disease. Many patients respond to oral gluco- reduction in skin score of 48% overall. In the 10th corticoids3 and others respond to a combination of oral glu- patient, skin scores and oral involvement improved on cocorticoids and cyclosporin A.4 Refractory chronic GVHD twice monthly ECP but deteriorated when reduced to has been successfully treated with other agents including once monthly. The final patient died from renal failure azathioprine, thalidomide5 and photochemotherapy in the secondary to cyclosporin toxicity. Two out of five form of PUVA.6–10 There have also been a number of anec- patients with lung involvement showed a mild improve- dotal case reports11–13 and small studies14,15 reporting the ment in pulmonary function tests. Liver function tests success of extracorporeal photopheresis (ECP). were abnormal in five patients; they improved in one The aim of our study was to assess the safety and effi- and deteriorated in three. All patients receiving con- cacy of UVAR/UVADEX ECP (Therakos UK, Bracknell, comitant immunosuppressive/steroid therapy were able UK), in the treatment of patients with skin manifestations to reduce drug dosages by trial completion. Our results of chronic GVHD which had failed to respond to indicate that ECP can benefit patients with cutaneous standard therapies. and mucosal chronic GVHD who have failed on first- and second-line therapies. The effect on the systemic manifestations of GVHD is less consistent. Patients and methods Keywords: extracorporeal photopheresis; graft-versus- host disease; bone marrow transplantation Eleven adult patients of median age 40 years (range 18–47 years) were studied. All had received HLA-matched bone marrow transplants for haematological malignancies, from sibling (n = 8) or unrelated (n = 3) donors. They were Graft-versus-host disease (GVHD) is a frequent and major recruited nationally from Haematology and Dermatology complication of allogeneic stem cell transplantation. It is a departments within the United Kingdom. They were treated systemic disease with prominent cutaneous manifestations. at two centres: the Department of Haematology, Rotherham Ͻ It occurs either as an acute ( 100 days post- District General Hospital (patients 1–6) and St John’s Insti- Ͼ transplantation) or a chronic ( 100 days post- tute of Dermatology, St Thomas’ Hospital, London transplantation) disease and contributes significantly to (patients 7–11). Informed consent to take part in the study was obtained from all patients and approval from the local ethics committees had been granted. All patients had Correspondence: Dr F Child, Skin Tumour Unit, St John’s Institute of Dermatology, St Thomas’ Hospital, Lambeth Palace Road, London SE1 chronic cutaneous GVHD, and all had failed to respond to 7EH, UK conventional immunosuppressive protocols. All patients Received 3 September 1998; accepted 26 November 1998 had at least one of the following clinical features: Extracorporeal photopheresis in chronic GVHD FJ Child et al 882 (1) skin thickening, sclerosis, hyper- or hypo-pigmentation, pheresis bowl, saving the plasma and buffy coat layers. or ulceration; Forty millilitres of buffy coat and a volume of plasma were (2) joint contractures or fascial thickening; collected during each cycle. The red blood cells and all (3) oral ulceration; additional plasma were reinfused into the patient before (4) lichenoid skin changes. beginning the next collection cycle. Two hundred microgrammes of UVADEX were injected into the buffy The clinical data on all patients enrolled in the study are coat bag at the end of the first cycle. shown in Table 1. The median time from onset of chronic Photoinactivation of the leukocyte-enriched blood began GVHD to start of ECP therapy was 17 months (range 5– during the first cycle of buffy coat collection. Plasma and 59 months). Five patients had AML, three had ALL, two buffy coat were mixed with 200 ml of heparinized saline, had CML and one had multiple myeloma. Four patients had followed by pumping of the mixture continuously through mucosal involvement and five had pulmonary involvement. the photoactivation chamber where they were exposed to Three patients received ECP alone (patients 2, 3 and 8); UVA light; the tubing within the chamber was of uniform the remainder received additional steroids and/or immuno- thickness, allowing homogenous penetration of the UVA. suppressive therapy. Two were treated with prednisolone During the irradiation phase, UVADEX is activated by alone (patients 7 and 10), two with prednisolone and cyclo- UVA light, with concomitant pyrimidine base cross-linking sporin A (patients 6 and 11), patient 4 was taking predniso- of DNA in the leukocytes. The total photopheresis process lone and azathioprine, patient 5 was taking azathioprine took 3–4 h and treatment was performed on 2 consecu- and cyclosporin A and the other 2 patients (1 and 9) were tive days. taking a combination of prednisolone, azathioprine and cyclosporin A. Treatment protocol The following criteria were also fulfilled: haemoglobin Ͼ9 g/dl, platelets Ͼ20 × 109/l, neutrophils Ͼ1 × 109/l; body Patients were treated with ECP twice monthly for the first weight of Ͼ40 kg and adequate cardiac function to 4 months and were assessed clinically at 0, 4, 8 and 14 tolerate ECP. weeks. Wherever possible patients were kept on a constant dose of concomitant immunosuppressive therapy. After 4 ECP procedure months, ECP was continued once monthly for a further 3 months. Those who continued to improve were maintained Using the UVAR/UVADEX (liquid methoxsalen) system on monthly ECP following completion of the study. (Therakos UK) this involved collection of leukocyte- enriched blood, photoactivation and then reinfusion of the Cutaneous evaluation blood. Venous access was obtained peripherally or via a Hickman line and aliquots of whole blood were removed. Skin involvement was assessed by a member of the team Three hundred millilitres of plasma and 240 ml of buffy trained in the appropriate method of skin scoring. All mem- coat were separated and saved in six cycles of blood collec- bers involved in skin scoring had received a common train- tion, centrifugation and reinfusion. During each cycle, ing. Each individual patient was skin scored by the same whole blood was centrifuged and separated in a paediatric team member at each visit. Assessments were carried out Table 1 Clinical data on all patients enrolled in the study Patient 1 2 3 4 5 6 7 8 9 10 11 Age/sex 41/M 28/M 36/M 44/M 47/M 18/M 46/F 28/M 37/M 47/M 40/F Disease CML ALL AML AML AML ALL AML AML ALL IgA MM CML Donor sibling sibling sibling sibling sibling sibling MUD sibling MUD sibling MUD Onset GVHD 13 32 4 7 7 4 3 4 46 7 1 (months post-BMT) Disease type progressive progressive de-novo de-novo de-novo quiescent de-novo progressive de-novo progressive progressive Organs involved Skin + +++++++++ + Mucosal − −−+−−+−++ − Lung + +++−+−−−− − Liver + −++−−+−+− + Treatment Pre-ECP Prednisolone + −++−+++++ + Cyclosporin A + −−+++−++− + Azathioprine − −++++−−++ − Thalidomide + −−+−−−−−− + PUVA + +−−−−+−−− − Study completed yes yes no yes yes yes yes yes yes yes no MM = multiple myeloma. Extracorporeal photopheresis in chronic GVHD FJ Child et al 883 at 0, 4, 8 and 14 weeks, 6 months and at study completion. he had withdrawn from the trial after 4 months. Patient 5 Skin biopsies were taken from representative areas prior experienced an almost complete response. Figure 2 illus- to starting ECP to confirm the presence of predominantly trates the improvement in skin disease in patient 2 who lichenoid or sclerodermoid histological features. However, achieved a 63% reduction in skin score by study com- histology was not used to assess the effect of ECP as sclero- pletion. Six patients were able to reduce their dose of con- dermoid changes are difficult to grade histologically. comitant prednisolone (patients 1, 4, 6, 7, 9, 10); the dose Lichenoid changes histologically were represented clini- of cyclosporin A was also reduced in patient 1 and the dose cally by either erythema and scaling or papules.
Load more

Recommended publications
  • Extracorporeal Photopheresis for the Treatment of Refractory Chronic Graft-Versus-Host Disease
    Request for Medicare National Coverage Determination: Extracorporeal Photopheresis for the Treatment of Refractory Chronic Graft-Versus-Host Disease April 16, 2006 Submitted by: Therakos Inc. 437 Creamery Way Exton, PA 19341 Contact information: Dennis DeCola VP of Compliance and Scientific Affairs Tel: 610-280-1004 Fax: 610-280-1087 E-Mail: [email protected] Request for National Coverage Determination Extracorporeal Photopheresis for Refractory Chronic Graft-Versus-Host Disease April 16, 2006 Page 1 Statement of request Under the National Coverage Determination process, Therakos requests that CMS ex- pand its coverage of Extracorporeal photopheresis (ECP) to include extensive chronic graft-versus-host disease (cGVHD) that has failed to respond to corticosteroids and standard immunosuppressive drug therapy. Specifically, we propose coverage criteria that qualifying Medicare-eligible patients have documented extensive cGVHD that is re­ fractory or resistant to conventional immunosuppressive drug therapy, or are corticoster­ oid-dependent and require dose reduction to abrogate or diminish the risk of infectious or other complications related to high-dose corticosteroid and other immunosuppressive drug therapy. This application of photopheresis is (1) supported by an extensive publication record which documents both efficacy in achieving durable remissions and steroid- and drug- sparing benefit, (2) is widely used in clinical practice in the U.S., and (3) is almost uni­ versally covered by commercial U.S. insurers for the privately insured non-Medicare population. Description of the extracorporeal photopheresis procedure Extracorporeal photopheresis (ECP), also sometimes referred to as extracorporeal photo- chemotherapy, is a highly specialized procedure designed to induce apoptosis in ap­ proximately 10-15% of circulating T-lymphocytes and other leukocytes captured in the buffy coat phase of the patient’s blood.
    [Show full text]
  • Immunological Mechanisms of Extracorporeal Photopheresis in Cutaneous T Cell Lymphoma and Graft Versus Host Disease
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2012 IMMUNOLOGICAL MECHANISMS OF EXTRACORPOREAL PHOTOPHERESIS IN CUTANEOUS T CELL LYMPHOMA AND GRAFT VERSUS HOST DISEASE Lisa Shiue Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Immunopathology Commons, Immunoprophylaxis and Therapy Commons, Medicine and Health Sciences Commons, and the Other Immunology and Infectious Disease Commons Recommended Citation Shiue, Lisa, "IMMUNOLOGICAL MECHANISMS OF EXTRACORPOREAL PHOTOPHERESIS IN CUTANEOUS T CELL LYMPHOMA AND GRAFT VERSUS HOST DISEASE" (2012). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 327. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/327 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. IMMUNOLOGICAL MECHANISMS OF EXTRACORPOREAL PHOTOPHERESIS IN CUTANEOUS T CELL LYMPHOMA AND GRAFT VERSUS HOST DISEASE by Lisa Harn-Ging Shiue, B.S. APPROVED: ________________________________________ Madeleine Duvic, M.D., Supervisory Professor _______________________________ Amin Alousi, M.D. ________________________________ Wei Cao, Ph.D. _________________________________ Dorothy Lewis, Ph.D. ______________________________ Greg Lizee, Ph.D.
    [Show full text]
  • ECP) (ECP) • Review ECP Side-Effects, Patient Education and Hazardous Drug Aspects
    12/10/2014 Objectives Acute Graft-Versus-Host Disease • Explain the mechanics of extracorporeal and Extracorporeal Photopheresis photopheresis (ECP) (ECP) • Review ECP side-effects, patient education and hazardous drug aspects LCDR Tracey Chinn, RN, BSN, MPM • Discuss therapy impact to the Clinical Assistant to the Chief, ETIB, NCI inpatient/outpatient Nurse Technical Considerations: Technical Considerations Apheresis Instrument • Cellex (Therakos, Inc.) ▫ Single and double venous access • Uvar XTS (Therakos, Inc.) ▫ Single venous-access only ▫ Current NIH instrument ECP: The Mechanics Technical Considerations: Venous Access 1. Blood is drawn and separated thru centrifugation; WBC are separated and • Apheresis specialist should perform venous collected assessment and make recommendations 2. Plasma and RBCs returned to patient 3. Methoxsalen (Uvadex®) added to the WBC • Peripheral Venous Access 4. Medicated WBC cells exposed to UVA light, ▫ Average needle size = 17-18 gauge which activates the medication ▫ Needle is placed and removed at time of therapy 5. Treated WBC returned to patient; prompt an immune response 1 12/10/2014 Technical Considerations: Technical Considerations: Venous Access Extracorporeal Volume (ECV) • CVAD Access • ECV = Safe mL/whole blood can be taken out of ▫ Typical catheter/size = 9.6 french single-lumen body at one period of time Hickman ▫ NURS – CVAD Flushing Guidelines: “Dialysis/Apheresis –All Purpose Use” • ECV < 15% TBV (Total Blood Volume) ▫ Preference = Use ONLY for therapy • ECV is directly related to: ▫ Safety / Bowl size / Blood prime (< 20 kg) ▫ # Cycles performed = # WBC treated Technical Considerations: Technical Considerations: Extracorporeal Volume (ECV) Extracorporeal Volume (ECV) • Average adult total blood volume = 7- 8% of • Example: body weight ▫ 55 kg (weight) x 70 mL/kg = 3850 mL (TBV) • TBV = patient weight (kg) x body build (mL/kg) ▫ 3850 mL (TBV) x 0.15 = 577 mL (ECV) ▫ Normal build = 70 mL/kg of body weight ▫ Varies based on body build (i.e.
    [Show full text]
  • Extracorporeal Photochemotherapy) Reference Number: HNCA.CP.MP.291 Effective Date: 09/06 Coding Implications Last Review Date: 03/21 Revision Log
    Clinical Policy: Photopheresis (Extracorporeal Photochemotherapy) Reference Number: HNCA.CP.MP.291 Effective Date: 09/06 Coding Implications Last Review Date: 03/21 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Extracorporeal photochemotherapy (ECP), also called photopheresis, is a cell-based immunomodulatory therapy that involves collecting leukocytes from peripheral blood. These cells are exposed to a photosensitizing agent, 8-methoxypsoralen, and are then treated with ultraviolet radiation, after which they are re-infused. This procedure, which results in crosslinking of pyrimidine bases in DNA, produces massive apoptosis of the treated cells. The mechanism of action has not been fully elucidated, however, it is likely that photopheresis activates antigen-presenting cells, such that tumor-related antigens are more readily presented to cytoxic T cells. Policy/Criteria I. It is the policy of Health Net of California that extracorporeal photochemotherapy/photopheresis is medically necessary for the treatment of any of the following: A. Advanced or refractory erythrodermic variants of cutaneous T-cell lymphoma (e.g., mycosis fungoides, Sézary’s syndrome); B. Treatment or prevention of acute or chronic graft-versus-host disease refractory to standard immunosuppressive therapy; C. Heart or heart-lung transplant rejection when rejection episodes are refractory to high- dose steroids plus two or more of the following, unless contraindicated: 1. Cyclosporine; 2. Azathioprine; 3. Methotrexate; 4. Polyclonal and monoclonal antilymphocyte agents (e.g., antilymphocyte globulin ALG], antithymocyte globulin [ATG], OKT3 [monoclonal T-cell antibody]); D. Lung transplant rejection in individuals who are refractory to or intolerant of standard therapy. II.
    [Show full text]
  • Current Research of Extracorporeal Photopheresis and Future
    Extracorporeal Photopheresis are then dispatched to the infected site. For example, the foliative dermatitis, and adenopathy (inflammation of the Current Research of Extracorporeal Photopheresis and Th-1 response is mediated by CD4+ helper T-cells and lymph nodes). Patients with SS do not have a good prog- Future Applications CD8+ T-5 cells that secrete IFN-γ, IL-2, and IL-12 to fight nosis; there is an average survival rate of only 3 years against viruses. The CD4+ helper cells then “help” to in- (Scarisbrick, et al, 2001). SS patients have been found to Chaim Lederer voke a cytotoxic attack against the virus, mainly through have a high rate of Staph colonization. Secondary and hos- CD8+ cytotoxic T-cells (Steinman, Hemmi, 2006) pital acquired infections, most often from Staphylococcus Abstract (Kadowaki, 2007) . aureus (Staph) sepsis due to an impaired immune system, breaks in the skin and use of catheters are particularly fatal Photopheresis, also known as Extracorporeal Photopheresis (ECP) is making inroads in treatment of previously untreata- Located in the immune system, T-regulatory cells in SS patients. The cause of SS is unknown and the diag- ble diseases. As the medical world has delved deeper into, Although the mechanisms of photopheresis are largely un- (T-regs) regulate a wide variety of immune cells such as nosis is very difficult due to its similarities to other skin ail- known, increasingly detailed studies have proven its efficacy. The lack of side effects has made photopheresis an ideal CD4+, CD8+, B-cells, natural killer T-cells, and antigen pre- ments. It was originally believed that SS was derived from option for patients.
    [Show full text]
  • The Need for Individualized Procedures in ECP, the European Perspective!
    The Need for Individualized Procedures in ECP, the European Perspective! Volker Witt, MD St. Anna Kinderspital, Vienna, Austria ECP = extrcorporeal photopheresis 1 2 3 4 15.01.2015 2 What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Preparing a buffy coat • Adding a Photosensitizer • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Apheresis • Preparing a buffy coat • Inline systems • Offline systems • Adding a Photosensitizer • To draw peripheral blood • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Directly from the Apheresis • Preparing a buffy coat device • Adding a Photosensitizer • Diluted by plasma • Transferring in a irradiation • Diluted by saline solution disposable • Hematocrit • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • 8-MOP • Preparing a buffy coat • Final concentration (?) • Adding a Photosensitizer • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Chamber • Preparing a buffy coat • Bag • Adding a Photosensitizer • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • In a pivoting a bag • Preparing
    [Show full text]
  • Guidelines for Use of Extracorporeal Photopheresis in Acute Graft-Versus-Host Disease (GVHD) Bryan A
    Washington University School of Medicine Digital Commons@Becker Kidneycentric Kidneycentric 12-2015 Guidelines for use of extracorporeal photopheresis in acute graft-versus-host disease (GVHD) Bryan A. Sisk Washington University School of Medicine in St. Louis Follow this and additional works at: http://digitalcommons.wustl.edu/kidneycentric_all Recommended Citation Sisk, Bryan A., "Guidelines for use of extracorporeal photopheresis in acute graft-versus-host disease (GVHD)" (2015). Kidneycentric. Paper 11. http://digitalcommons.wustl.edu/kidneycentric_all/11 This Article is brought to you for free and open access by the Kidneycentric at Digital Commons@Becker. It has been accepted for inclusion in Kidneycentric by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Guidelines for Use of Extracorporeal Photopheresis in Acute Graft-Versus-Host Disease (GVHD) Bryan Sisk, MD 7/18/2015 History: The first investigational study on the use of extracorporeal photopheresis (ECP) was published in 1987, and focused on treatment of cutaneous T-cell lymphoma.1 This study led the FDA to approve of photopheresis. Although T-cell lymphoma is the only FDA approved indication for photopheresis its therapeutic use has expanded to a number of other disease processes, most notably acute and chronic graft versus host disease (GVHD). Photopheresis Procedure: ECP is a leukapheresis-based therapy. Whole blood is processed outside of the body in the following way: whole blood is drawn from a catheter placed in a central vein; using centrifugation the different constituents of blood are separated based upon density i.e. white blood cells (WBC) separate into the buffy coat which can distinguished from red blood cells (RBCs) and plasma.2 The RBCs and plasma are returned to the patient, but the buffy coat containing the WBCs is isolated (it should be noted that only 5-10% of the patients WBCs are typically captured during the procedure).
    [Show full text]
  • Extracorporeal Photopheresis Practice Patterns: an International Survey by the ASFA ECP Subcommittee
    Received: 2 May 2016 | Revised: 30 June 2016 | Accepted: 1 July 2016 DOI 10.1002/jca.21486 RESEARCH ARTICLE Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee Nancy M. Dunbar1 | Jay S. Raval2 | Andrew Johnson3 | Cori M. Abikoff4 | Jill Adamski5 | Laura L. Cooling6 | Brenda Grossman7 | Haewon C. Kim8 | Marisa B. Marques9 | Shanna Morgan3,10,11 | Amy E. Schmidt12 | Steven R. Sloan13 | Leon L. Su14 | Zbigniew M. Szczepiorkowski1,17 | F. Bernadette West4 | Edward Wong15 | Jennifer Schneiderman16 1 Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Abstract Center, Lebanon NH Background: Although many apheresis centers offer extracorporeal photopheresis 2 Department of Pathology and Laboratory Medicine, University of North Carolina, (ECP), little is known about current treatment practices. Chapel Hill, NC Methods: An electronic survey was distributed to assess ECP practice 3 Department of Laboratory Medicine and Pathology, University of Minnesota, internationally. Minneapolis, MN Results: Of 251 responses, 137 met criteria for analysis. Most respondents were 4 Department of Pediatrics, New York from North America (80%). Nurses perform ECP at most centers (84%) and the Medical College, Valhalla, NY majority of centers treat adults only (52%). Most centers treat fewer than 50 patients/ 5 Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ year (83%) and perform fewer than 300 procedures/year (70%). Closed system 6 Department of Pathology, University of devices (XTS and/or Cellex) are used to perform ECP at most centers (96%). The Michigan School of Medicine, Ann Arbor, most common indications for ECP are acute/chronic skin graft versus host disease MI (89%) and cutaneous T-cell lymphoma (63%).
    [Show full text]
  • Cryopreservation As a Way to Maintain Extracorporeal Photopheresis Regimen for Gvhd Treatment While Circumventing Patient Temporary Inability to Undergo Apheresis
    Bone Marrow Transplantation (2017) 52, 167–170 © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0268-3369/17 www.nature.com/bmt LETTER TO THE EDITOR Cryopreservation as a way to maintain extracorporeal photopheresis regimen for GvHD treatment while circumventing patient temporary inability to undergo apheresis Bone Marrow Transplantation (2017) 52, 167–170; doi:10.1038/ Nucleated cells were quantified using the pocH-100i device bmt.2016.240; published online 19 September 2016 (Sysmex, Villepinte, France). Cell viability was analyzed by flow cytometry using 7-aminoActinomycin D. CD3+ and CD14+ cells were quantified by FACS analysis, only in the Nancy center. Extracorporeal photopheresis (ECP) is a safe treatment in patients In both centers, the same treatment regimen was used with at with mild acute or chronic GvHD.1–3 However, its clinical use is least 3 ECP (fresh or ‘cryo-ECP’) per week for acute GvHD, and 1 sometimes limited by logistical problems that compromise or 2 ECP per week (depending on GvHD grade) for chronic or late repeated aphereses, especially venous access failure. acute GVHD, until clinical improvement. Merlin et al.4 previously concluded that cryopreservation The clinical severity of acute GvHD was determined as defined 5 before irradiation did not impair WBC functional capabilities. in the 1994 consensus conference criteria. The severity of chronic The hematopoietic stem cell transplantation (HSCT) centers of GvHD was determined as per the 2005 National Institutes of 6 Nancy and Clermont-Ferrand (CF) University Hospitals Health (NIH) consensus guidelines. Response was retrospectively investigated the use of frozen and thawed WBC (FTWBC, assessed at 1, 3 and 6 months in all patients.
    [Show full text]
  • The Role of Photopheresis in the Treatment of Bronchiolitis Obliterans Syndrome
    The Role of Photopheresis in the Treatment of Bronchiolitis Obliterans Syndrome Selim M. Arcasoy, M.D. Medical Program Director Lung Transplantation Program NewYork-Presbyterian Hospital Columbia University Medical Center New York, NY Terminology/Definitions • OB=BO: Obliterative bronchiolitis or bronchiolitis obliterans • Histopathologic term used to describe the finding of fibrous obliteration of small airways after LTx • BOS: Bronchiolitis obliterans syndrome • Clinical/physiologic definition of chronic lung allograft dysfunction caused by OB and characterized by progressive airflow limitation • Term originally proposed in 1993 and revised in 2002 Bronchiolitis Obliterans Syndrome Clinical Impact Very common and deadly • Cumulative risk of 50-80% between 5 and 10 years after lung transplantation • Leading cause of long-term mortality • Directly or indirectly accounts for at least 30 to 50% of deaths after third post-operative year • Less than 40% survival at 5 years after its onset Injury to airway epithelium Normal Alloimmune or non-alloimmune Pathogenesis of OB (rejection, infection, aspiration, ischemia) Inflammatory response Vascular changes Innate and adaptive immune response (PMN, macrophage, DC, T- and B-lymphocytes) Final common pathway IL-1, IL-2, IL-6, IL-8, IL-12, Repair response TNF-α, MCP-1, complement, Fibroblast proliferation IFN-γ, RANTES, ROS, NO, EC matrix deposition peroxides, leukotrienes TGF-ß,PDGF, IGF, FGF, ET-1 Mechanisms and Therapy of OB After Lung Tx Adapted from Nicod. Proc Am Thorac Soc 2006;3:444 Irritants/
    [Show full text]
  • Extracorporeal Photopheresis
    Medical Coverage Policy Effective Date ............................................05/15/2021 Next Review Date ......................................05/15/2022 Coverage Policy Number .................................. 0320 Extracorporeal Photopheresis Table of Contents Related Coverage Resources Overview .............................................................. 1 Heart, Lung and Heart-Lung Transplantation Coverage Policy ................................................... 1 Plasmapheresis General Background ............................................ 2 Medicare Coverage Determinations .................... 4 Coding/Billing Information .................................... 5 References .......................................................... 5 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For
    [Show full text]
  • 8.01.36 Extracorporeal Photopheresis BCBSA Ref
    MEDICAL POLICY – 8.01.36 Extracorporeal Photopheresis BCBSA Ref. Policy: 8.01.36 Effective Date: April 1, 2021 RELATED MEDICAL POLICIES: Last Revised: Mar. 23, 2021 5.01.532 Cutaneous T-Cell Lymphomas (CTCL): Systemic Therapies Replaces: 8.01.501 Select a hyperlink below to be directed to that section. POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction Extracorporeal photopheresis is a treatment of white blood cells. Blood is withdrawn and a specialized machine separates the whole blood into its different components — red blood cells, white blood, cells, platelets, and plasma. White blood cells are kept back and the rest of the blood is returned to the patient. The white blood cells are mixed with medication that makes them sensitive to ultraviolet light. After being exposed to ultraviolet light, the white blood cells are returned to the patient. White blood cells are part of the immune system, and treating them in this way stimulates the immune system. High quality medical studies have shown this technique is successful in treating a number of conditions. These include organ rejection after a heart transplant, graft-versus-host disease, and cutaneous T-cell lymphoma in certain situations. It has also been proposed to treat a number of autoimmune conditions, like Crohn disease or multiple sclerosis. Because more medical studies are needed to show if it works for other conditions, using this technique for autoimmune conditions is investigational (unproven). Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria.
    [Show full text]